Histone Readers MLLT1 and MLLT3 Concentrate AID for Locus Specificity

Researchers have identified a critical mechanism by which the enzyme activation-induced deaminase (AID) achieves locus specificity during B cell somatic hypermutation, a process essential for generating antibody diversity. Published online on September 30, 2026, in the journal Nature, the study details how the histone readers MLLT1 and MLLT3 play a pivotal role in concentrating AID activity to specific target regions within the genome. This targeted action is crucial for preventing widespread off-target mutagenesis, which could otherwise lead to detrimental genetic alterations in B cells.

The research elucidates that MLLT1 and MLLT3 act as molecular anchors, binding to specific histone modifications and thereby recruiting AID to particular DNA loci. This recruitment is not random; it is dictated by the unique epigenetic landscape of these target sites. By restricting AID's access to these designated areas, the MLLT1–MLLT3 complex ensures that the enzyme's powerful DNA-modifying capabilities are utilized precisely where needed for antibody gene diversification. This precise localization is fundamental to the efficiency and safety of somatic hypermutation, a process that involves introducing point mutations into immunoglobulin genes to enhance antibody affinity.

Somatic hypermutation, a hallmark of adaptive immunity, allows B cells to fine-tune their antibody production in response to pathogens. AID is the key enzyme that initiates this process by deaminating cytosine bases in DNA. However, AID's inherent activity poses a risk of unintended mutations if not carefully controlled. The findings presented in Nature underscore the sophisticated regulatory network in place to manage AID function. The concentration of AID activity by MLLT1 and MLLT3 is a prime example of how cellular machinery ensures that a potent but potentially dangerous enzyme operates with high fidelity, targeting only specific genomic sites.

This discovery has significant implications for understanding B cell development and the origins of certain B cell-related diseases. Dysregulation of AID activity or its targeting mechanisms has been implicated in the development of lymphomas and other lymphoid malignancies. By clarifying the role of MLLT1 and MLLT3 in conferring locus specificity, this research provides a deeper insight into the molecular underpinnings of immune system function and offers potential avenues for therapeutic interventions aimed at correcting aberrant AID activity. The study, published with the digital object identifier 10.1038/s41586-026-11087-1, contributes to the growing body of knowledge on epigenetic regulation and its impact on cellular processes.